UCB and Biogen report dapirolizumab pegol shows higher response versus placebo in post-hoc PHOENYCS GO analyses

UCB and Biogen report that dapirolizumab pegol plus standard of care was associated with higher response versus placebo on the novel TRM-SLE measure and greater sustained low disease activity in post-hoc Phase 3 PHOENYCS GO analyses.

Detected & updated continuously · Source: Nebula